Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: A multicenter study based on real-world data

• Main Authors: Rungroj Krittayaphong, Vip Viprakasit, Pairash Saiviroonporn, Noppadol Siritanaratkul, Suvipaporn Siripornpitak, Arunotai Meekaewkunchorn, Thawatchai Kirawittaya, Pornpun Sripornsawan, Arunee Jetsrisuparb, Jiraporn Srinakarin, Peerapon Wong, Nuttaporntira Phalakornkul, Phakatip Sinlapamongkolkul, John Wood
• Other Authors: Mahidol University
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/41850

© 2017 Elsevier Inc. Prevalence of cardiac and liver iron overload in patients with thalassemia in real-world practice may vary among different regions especially in the era of widely-used iron chelation therapy. The aim of this study was to determine the prevalence of cardiac and liver iron overload in and the management patterns of patients with thalassemia in real-world practice in Thailand. We established a multicenter registry for patients with thalassemia who underwent magnetic resonance imaging (MRI) as part of their clinical evaluation. All enrolled patients underwent cardiac and liver MRI for assessment of iron overload. There were a total of 405 patients enrolled in this study. The mean age of patients was 18.8 ± 12.5 years and 46.7% were male. Two hundred ninety-six (73.1%) of patients received regular blood transfusion. Prevalence of cardiac iron overload (CIO) and liver iron overload (LIO) was 5.2% and 56.8%, respectively. Independent predictors for iron overload from laboratory information were serum ferritin and transaminase for both CIO and LIO. Serum ferritin can be used as a screening tool to rule-out CIO and to diagnose LIO. Iron chelation therapy was given in 74.6%; 15.3% as a combination therapy.